10-K Filing

GUARDANT HEALTH, INC. CIK: 1576280 FY 2022

Filing Information

Form Type	10-K
Accession Number	`0001576280-23-000020`
Period End Date	20221231
Filing Date	20230223
Fiscal Year	2022
Fiscal Period	FY
XBRL Instance	gh-20221231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 82 Income Statement 72 Cash Flow Statement 153 Stockholders Equity 42 Comprehensive Income 21

Balance Sheet 82 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$492.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$141.65M	USD	Point-in-time
Short-term marketable debt securities	`MarketableSecuritiesCurrent`	$440.55M	USD	Point-in-time
Short-term marketable debt securities	`MarketableSecuritiesCurrent`	$869.58M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$97.26M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$97.65M	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Preferred stock, par value (in usd per share)	`PreferredStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory, net	`InventoryNet`	$51.60M	USD	Point-in-time
Inventory, net	`InventoryNet`	$30.67M	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$53.05M	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$31.51M	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.19B	USD	Point-in-time
Preferred stock, shares issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$1.11B	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Long-term marketable debt securities	`MarketableSecuritiesNoncurrent`	$698.03M	USD	Point-in-time
Preferred stock, shares outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Long-term marketable debt securities	`MarketableSecuritiesNoncurrent`	-	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$124.46M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$167.92M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$189.44M	USD	Point-in-time
Right-of-use assets, net	`OperatingLeaseRightOfUseAsset`	$174.00M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$14.21M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	102.62M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.77M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$11.73M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.77M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	102.62M	shares	Point-in-time
Variable interest entity, assets	`Assets`	$1.61B	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$61.45M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$60.94M	USD	Point-in-time
Variable interest entity, assets	`Assets`	$2.20B	USD	Point-in-time
Variable interest entity, liabilities	`Liabilities`	$1.55B	USD	Point-in-time
Variable interest entity, liabilities	`Liabilities`	$1.56B	USD	Point-in-time
Total Assets	`Assets`	$1.61B	USD	Point-in-time
Total Assets	`Assets`	$2.20B	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$175.82M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$105.36M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$17.40M	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$11.33M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$194.69M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$193.22M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.14B	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.13B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$210.01M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$226.05M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$9.18M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$3.93M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.55B	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.56B	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 2021	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 2021	`PreferredStockValueOutstanding`	-	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2022 and 2021; 102,619,383 and 101,767,446 shares issued and outstanding as of December 31, 2022 and 2021, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2022 and 2021; 102,619,383 and 101,767,446 shares issued and outstanding as of December 31, 2022 and 2021, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.66B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.74B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-19.52M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.76M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.66B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.01B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$60.18M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$645.00M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$798.39M	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.20B	USD	Point-in-time
Total Liabilities and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$1.61B	USD	Point-in-time

Income Statement 72 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$236.32M	USD	Annual
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$392.05M	USD	Annual
Precision oncology testing	`RevenueFromPrecisionOncologyTesting`	$304.31M	USD	Annual
Development services and other	`RevenueFromDevelopmentServices`	$57.49M	USD	Annual
Development services and other	`RevenueFromDevelopmentServices`	$69.34M	USD	Annual
Development services and other	`RevenueFromDevelopmentServices`	$50.41M	USD	Annual
Total revenue	`Revenues`	$286.73M	USD	Annual
Total revenue	`Revenues`	$449.54M	USD	Annual
Total revenue	`Revenues`	$373.65M	USD	Annual
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$74.77M	USD	Annual
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$110.40M	USD	Annual
Cost of precision oncology testing	`CostsOfPrecisionOncologyTesting`	$148.20M	USD	Annual
Cost of development services and other	`CostOfDevelopmentServices`	$8.13M	USD	Annual
Cost of development services and other	`CostOfDevelopmentServices`	$17.77M	USD	Annual
Cost of development services and other	`CostOfDevelopmentServices`	$12.52M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$149.86M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$263.22M	USD	Annual
Research and development expense	`ResearchAndDevelopmentExpense`	$373.81M	USD	Annual
Sales and marketing expense	`SellingAndMarketingExpense`	$106.51M	USD	Annual
Sales and marketing expense	`SellingAndMarketingExpense`	$191.88M	USD	Annual
Sales and marketing expense	`SellingAndMarketingExpense`	$299.83M	USD	Annual
General and administrative expense	`GeneralAndAdministrativeExpense`	$192.77M	USD	Annual
General and administrative expense	`GeneralAndAdministrativeExpense`	$206.64M	USD	Annual
General and administrative expense	`GeneralAndAdministrativeExpense`	$163.96M	USD	Annual
Total costs and operating expenses	`CostsAndExpenses`	$541.68M	USD	Annual
Total costs and operating expenses	`CostsAndExpenses`	$784.65M	USD	Annual
Total costs and operating expenses	`CostsAndExpenses`	$993.92M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-411.00M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-254.95M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-544.38M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$3.93M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$6.07M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$10.17M	USD	Annual
Interest expense	`InterestExpense`	$2.58M	USD	Annual
Interest expense	`InterestExpense`	$2.58M	USD	Annual
Interest expense	`InterestExpense`	$4.77M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$25.18M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-12.78M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$3.64M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	$-99.78M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	-	USD	Annual
Fair value adjustments of noncontrolling interest liability	`FairValueOptionChangesInFairValueGainLoss1`	-	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-653.45M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-245.90M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-384.47M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$1.14M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$300.00K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$379.00K	USD	Annual
Net loss	`ProfitLoss`	$-654.59M	USD	Annual
Net loss	`ProfitLoss`	$-384.77M	USD	Annual
Net loss	`ProfitLoss`	$-246.28M	USD	Annual
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$7.50M	USD	Annual
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$20.90M	USD	Annual
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	-	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - basic	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-654.59M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - basic	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-253.78M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - basic	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-405.67M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-405.67M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-253.78M	USD	Annual
Net loss attributable to Guardant Health, Inc. common stockholders - diluted	`NetIncomeLossAvailableToCommonStockholdersDiluted`	$-654.59M	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-4.00	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-2.60	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)	`EarningsPerShareBasic`	$-6.41	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-2.60	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-4.00	USD	Annual
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)	`EarningsPerShareDiluted`	$-6.41	USD	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	101.31M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	97.50M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	102.18M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	101.31M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	97.50M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	102.18M	shares	Annual

Cash Flow Statement 153 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-654.59M	USD	Annual
Net loss	`ProfitLoss`	$-384.77M	USD	Annual
Net loss	`ProfitLoss`	$-246.28M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$22.27M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$16.07M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$35.96M	USD	Annual
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$5.57M	USD	Annual
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$24.66M	USD	Annual
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$28.59M	USD	Annual
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	Annual
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	Annual
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	$8.50M	USD	Annual
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$4.30M	USD	Annual
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-120.00K	USD	Annual
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$2.38M	USD	Annual
Non-cash stock-based compensation	`ShareBasedCompensation`	$94.69M	USD	Annual
Non-cash stock-based compensation	`ShareBasedCompensation`	$151.45M	USD	Annual
Non-cash stock-based compensation	`ShareBasedCompensation`	$144.11M	USD	Annual
Amortization of debt discount and debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$2.56M	USD	Annual
Amortization of debt discount and debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$2.57M	USD	Annual
Amortization of debt discount and debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$4.73M	USD	Annual
Amortization of premium (discount) on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-12.85M	USD	Annual
Amortization of premium (discount) on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-4.59M	USD	Annual
Amortization of premium (discount) on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-4.02M	USD	Annual
Unrealized losses on marketable equity securities	`EquitySecuritiesFvNiUnrealizedGainLoss`	-	USD	Annual
Unrealized losses on marketable equity securities	`EquitySecuritiesFvNiUnrealizedGainLoss`	$-7.79M	USD	Annual
Unrealized losses on marketable equity securities	`EquitySecuritiesFvNiUnrealizedGainLoss`	-	USD	Annual
Impairment of other assets	`OtherAssetImpairmentCharges`	-	USD	Annual
Impairment of other assets	`OtherAssetImpairmentCharges`	-	USD	Annual
Impairment of other assets	`OtherAssetImpairmentCharges`	$5.26M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`IncomeTaxCreditsAndAdjustments`	-	USD	Annual
Fair value adjustments of noncontrolling interest liability	`IncomeTaxCreditsAndAdjustments`	$99.78M	USD	Annual
Fair value adjustments of noncontrolling interest liability	`IncomeTaxCreditsAndAdjustments`	-	USD	Annual
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	$-47.00K	USD	Annual
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	$-7.15M	USD	Annual
Credit loss adjustment and others	`OtherNoncashIncomeExpense`	$-21.00K	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$5.46M	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$44.35M	USD	Annual
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-375.00K	USD	Annual
Inventory, net	`IncreaseDecreaseInInventories`	$7.54M	USD	Annual
Inventory, net	`IncreaseDecreaseInInventories`	$7.96M	USD	Annual
Inventory, net	`IncreaseDecreaseInInventories`	$20.93M	USD	Annual
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-20.44M	USD	Annual
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$35.75M	USD	Annual
Prepaid expenses and other current assets, net	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$6.08M	USD	Annual
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$19.33M	USD	Annual
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$4.18M	USD	Annual
Other assets, net	`IncreaseDecreaseInOtherOperatingAssets`	$-11.70M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities`	$60.33M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities`	$34.80M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities`	$505.00K	USD	Annual
Operating lease liabilities	`LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets`	$-6.04M	USD	Annual
Operating lease liabilities	`LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets`	$14.21M	USD	Annual
Operating lease liabilities	`LongTermOperatingLeaseLiabilitiesNetOfRightOfUseAssets`	$-20.23M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$9.87M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$2.78M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-3.73M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-103.93M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-209.02M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-309.46M	USD	Annual
Purchase of marketable debt securities	`PaymentsToAcquireMarketableSecurities`	$303.76M	USD	Annual
Purchase of marketable debt securities	`PaymentsToAcquireMarketableSecurities`	$1.13B	USD	Annual
Purchase of marketable debt securities	`PaymentsToAcquireMarketableSecurities`	$900.81M	USD	Annual
Maturity of marketable debt securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$555.00M	USD	Annual
Maturity of marketable debt securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$562.55M	USD	Annual
Maturity of marketable debt securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$952.11M	USD	Annual
Purchase of non-marketable equity securities and other related assets	`PaymentsToAcquireEquitySecuritiesFvNi`	$23.97M	USD	Annual
Purchase of non-marketable equity securities and other related assets	`PaymentsToAcquireEquitySecuritiesFvNi`	-	USD	Annual
Purchase of non-marketable equity securities and other related assets	`PaymentsToAcquireEquitySecuritiesFvNi`	$39.42M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$77.46M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$36.17M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$75.03M	USD	Annual
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	$17.89M	USD	Annual
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-63.16M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-617.09M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$149.82M	USD	Annual
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$71.00K	USD	Annual
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$146.00K	USD	Annual
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$174.00K	USD	Annual
Proceeds from issuance of common stock under employee stock purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	$7.09M	USD	Annual
Proceeds from issuance of common stock under employee stock purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	$9.32M	USD	Annual
Proceeds from issuance of common stock under employee stock purchase plan	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans`	$9.75M	USD	Annual
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$8.11M	USD	Annual
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.62M	USD	Annual
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$9.53M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$3.45M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$83.76M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$7.88M	USD	Annual
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	-	USD	Annual
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	-	USD	Annual
Joint Venture Acquisition	`PaymentsForJointVentureAcquisitionFinancingActivities`	$177.78M	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	$-14.23M	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	-	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`NoncashTenderOfferIssued`	-	USD	Annual
Payment of contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	$1.06M	USD	Annual
Payment of contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	-	USD	Annual
Payment of contingent consideration	`PaymentForContingentConsiderationLiabilityFinancingActivities`	-	USD	Annual
Proceeds from public offerings of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from public offerings of common stock	`ProceedsFromIssuanceOfCommonStock`	$355.73M	USD	Annual
Proceeds from public offerings of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Payment of offering costs related to public offerings of common stock	`PaymentsOfStockIssuanceCosts`	$1.13M	USD	Annual
Payment of offering costs related to public offerings of common stock	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Payment of offering costs related to public offerings of common stock	`PaymentsOfStockIssuanceCosts`	-	USD	Annual
Proceeds from borrowings on convertible senior notes, net	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from borrowings on convertible senior notes, net	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from borrowings on convertible senior notes, net	`ProceedsFromConvertibleDebt`	$1.13B	USD	Annual
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	$784.00K	USD	Annual
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	Annual
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	Annual
Purchase of convertible note hedges	`PaymentsForHedgeFinancingActivities`	-	USD	Annual
Purchase of convertible note hedges	`PaymentsForHedgeFinancingActivities`	-	USD	Annual
Purchase of convertible note hedges	`PaymentsForHedgeFinancingActivities`	$90.05M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-189.09M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-66.82M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.41B	USD	Annual
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-1.60M	USD	Annual
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$455.00K	USD	Annual
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-1.69M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-350.34M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$689.75M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-340.69M	USD	Annual
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$141.95M	USD	Point-in-time
Cash, cash equivalents and restricted cash Beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$492.29M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$141.95M	USD	Point-in-time
Cash, cash equivalents and restricted cash End of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$13.12M	USD	Annual
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$4.07M	USD	Annual
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$171.38M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$331.00K	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$1.33M	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	$393.00K	USD	Annual
Purchase of property and equipment included in accounts payable and accrued liabilities	`IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid`	$8.29M	USD	Annual
Purchase of property and equipment included in accounts payable and accrued liabilities	`IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid`	$8.89M	USD	Annual
Purchase of property and equipment included in accounts payable and accrued liabilities	`IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid`	$1.99M	USD	Annual
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$47.00K	USD	Annual
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	-	USD	Annual
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$238.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$52.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$8.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$52.00K	USD	Annual
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	-	USD	Point-in-time
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	`InvestmentsPayable`	$78.00M	USD	Point-in-time
Debt issuance costs included in accounts payable and accrued liabilities	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	-	USD	Annual
Debt issuance costs included in accounts payable and accrued liabilities	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	$784.00K	USD	Annual
Debt issuance costs included in accounts payable and accrued liabilities	`DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction`	-	USD	Annual

Stockholders Equity 42 line items

Line Item	Tag	Value	Unit	Period
Issuance costs	`AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts`	$1.13M	USD	Annual
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-20.90M	USD	Annual
Adjustment of redeemable noncontrolling interest	`ReclassificationsOfTemporaryToPermanentEquity`	$-7.50M	USD	Annual
Beginning balance	`StockholdersEquity`	$60.18M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$645.00M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Issuance of common stock upon follow-on offering, net of offering costs (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	4.31M	shares	Point-in-time
Issuance of common stock upon follow-on offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	Annual
Issuance of common stock upon follow-on offering, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$354.60M	USD	Point-in-time
Equity component of convertible senior notes, net	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt`	$330.40M	USD	Annual
Purchase of convertible senior note hedges	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges`	$90.00M	USD	Annual
Purchase of convertible senior note hedges	`AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges`	$-90.05M	USD	Annual
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	693,074.00	shares	Annual
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	1.45M	shares	Annual
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	228,311.00	shares	Annual
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$8.11M	USD	Annual
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.62M	USD	Annual
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$9.53M	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$8.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$52.00K	USD	Annual
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$52.00K	USD	Annual
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$7.09M	USD	Annual
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$9.75M	USD	Annual
Common stock issued under employee stock purchase plan	`StockIssuedDuringPeriodValueEmployeeStockPurchasePlan`	$9.32M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$83.76M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$3.45M	USD	Annual
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$7.88M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$144.11M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$151.45M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$94.69M	USD	Annual
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	`AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued`	$14.23M	USD	Annual
Other comprehensive gain, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-14.76M	USD	Annual
Other comprehensive gain, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$1.59M	USD	Annual
Other comprehensive gain, net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-7.46M	USD	Annual
Net loss	`NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest`	$-654.59M	USD	Annual
Net loss	`NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest`	$-384.77M	USD	Annual
Net loss	`NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest`	$-246.28M	USD	Annual
Ending balance	`StockholdersEquity`	$60.18M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$645.00M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$798.39M	USD	Point-in-time

Comprehensive Income 21 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-654.59M	USD	Annual
Net loss	`ProfitLoss`	$-384.77M	USD	Annual
Net loss	`ProfitLoss`	$-246.28M	USD	Annual
Unrealized (loss) gain on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-5.77M	USD	Annual
Unrealized (loss) gain on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.13M	USD	Annual
Unrealized (loss) gain on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-13.16M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.69M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.60M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$455.00K	USD	Annual
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-14.76M	USD	Annual
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$1.59M	USD	Annual
Other comprehensive (loss) income	`OtherComprehensiveIncomeLossNetOfTax`	$-7.46M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-392.23M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-244.70M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-669.35M	USD	Annual
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$20.90M	USD	Annual
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	-	USD	Annual
Comprehensive loss attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$7.50M	USD	Annual
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-252.20M	USD	Annual
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-413.13M	USD	Annual
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-669.35M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.